Muscle Mass and Association to Quality of Life in Non-small Cell Lung Cancer Patients

Overview

Journal J Cachexia Sarcopenia Muscle

Date 2017 May 12

PMID 28493418

Citations 57

Authors

Asta Bye

Bjorg Sjoblom

Tore Wentzel-Larsen

Bjorn H Gronberg

Vickie E Baracos

Marianne J Hjermstad

Nina Aass

Roy M Bremnes

Oystein Flotten

Marit Jordhoy

Affiliations

Soon will be listed here.

Abstract

Background: Cancer wasting is characterized by muscle loss and may contribute to fatigue and poor quality of life (QoL). Our aim was to investigate associations between skeletal muscle index (SMI) and skeletal muscle radiodensity (SMD) and selected QoL outcomes in advanced non-small cell lung cancer (NSCLC) at diagnosis.

Methods: Baseline data from patients with stage IIIB/IV NSCLC and performance status 0-2 enrolled in three randomized trials of first-line chemotherapy (n = 1305) were analysed. Associations between SMI (cm /m ) and SMD (Hounsfield units) based on computed tomography-images at the third lumbar level and self-reported physical function (PF), role function (RF), global QoL, fatigue, and dyspnoea were investigated by linear regression using flexible non-linear modelling.

Results: Complete data were available for 734 patients, mean age 65 years. Mean SMI was 47.7 cm /m in men (n = 420) and 39.6 cm /m in women (n = 314). Low SMI values were non-linearly associated with low PF and RF (men P = 0.016/0.020, women P = 0.004/0.012) and with low global QoL (P = 0.001) in men. Low SMI was significantly associated with high fatigue (P = 0.002) and more pain (P = 0.015), in both genders, but not with dyspnoea. All regression analyses showed poorer physical outcomes below an SMI breakpoint of about 42-45 cm /m for men and 37-40 cm /m for women. In both genders, poor PF and more dyspnoea were significantly associated with low SMD.

Conclusions: Low muscle mass in NSCLC negatively affects the patients' PF, RF, and global QoL, possibly more so in men than in women. However, muscle mass must be below a threshold value before this effect can be detected.

Citing Articles

Survival impact and risk factors of skeletal muscle loss during first-line EGFR-TKIs therapy in advanced lung adenocarcinoma patients.

Nie X, Zou M, Song C, Zhang P, Ma D, Cui D BMC Cancer. 2025; 25(1):393.

PMID: 40038684 PMC: 11881361. DOI: 10.1186/s12885-025-13775-z.

Potential Benefits from Physical Exercise in Advanced Cancer Patients Undergoing Systemic Therapy? A Narrative Review of the Randomized Clinical Trials.

Bozzetti F Curr Oncol. 2024; 31(12):7631-7646.

PMID: 39727686 PMC: 11674197. DOI: 10.3390/curroncol31120563.

Gender-Specific Malnutrition and Muscle Depletion in Gastric and Colorectal Cancer: Role of Dietary Intake in a Jordanian Cohort.

Al-Bayyari N, Hailat M, Baylin A Nutrients. 2024; 16(23).

PMID: 39683394 PMC: 11644017. DOI: 10.3390/nu16234000.

Metabolic Reprogramming of Phospholipid Fatty Acids as a Signature of Lung Cancer Type.

Paunovic M, Stojanovic A, Pokimica B, Debeljak Martacic J, Cvetkovic Z, Ivanovic N Cancers (Basel). 2024; 16(19).

PMID: 39409945 PMC: 11475191. DOI: 10.3390/cancers16193320.

A sex-oriented analysis concerning skeletal muscle quantity and quality and associations to quality of life in hospitalized patients with cirrhosis.

Yang J, Guo G, Yang F, Li C, Wang H, Yang W Health Qual Life Outcomes. 2024; 22(1):78.

PMID: 39267044 PMC: 11395965. DOI: 10.1186/s12955-024-02295-2.

References

Gronberg B, Bremnes R, Flotten O, Amundsen T, Brunsvig P, Hjelde H . Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009; 27(19):3217-24. DOI: 10.1200/JCO.2008.20.9114. View

Baracos V . Cancer-associated cachexia and underlying biological mechanisms. Annu Rev Nutr. 2006; 26:435-61. DOI: 10.1146/annurev.nutr.26.061505.111151. View

Fearon K, Strasser F, Anker S, Bosaeus I, Bruera E, Fainsinger R . Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011; 12(5):489-95. DOI: 10.1016/S1470-2045(10)70218-7. View

Kazemi-Bajestani S, Mazurak V, Baracos V . Computed tomography-defined muscle and fat wasting are associated with cancer clinical outcomes. Semin Cell Dev Biol. 2015; 54:2-10. DOI: 10.1016/j.semcdb.2015.09.001. View

Sjoblom B, Gronberg B, Saltyte Benth J, Baracos V, Flotten O, Hjermstad M . Low muscle mass is associated with chemotherapy-induced haematological toxicity in advanced non-small cell lung cancer. Lung Cancer. 2015; 90(1):85-91. DOI: 10.1016/j.lungcan.2015.07.001. View

Temel J, Abernethy A, Currow D, Friend J, Duus E, Yan Y . Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 2016; 17(4):519-531. DOI: 10.1016/S1470-2045(15)00558-6. View

Bosaeus I . Nutritional support in multimodal therapy for cancer cachexia. Support Care Cancer. 2008; 16(5):447-51. DOI: 10.1007/s00520-007-0388-7. View

Morgensztern D, Ng S, Gao F, Govindan R . Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol. 2009; 5(1):29-33. DOI: 10.1097/JTO.0b013e3181c5920c. View

Durrleman S, Simon R . Flexible regression models with cubic splines. Stat Med. 1989; 8(5):551-61. DOI: 10.1002/sim.4780080504. View

10.

Triano L, Deshpande H, Gettinger S . Management of patients with advanced non-small cell lung cancer: current and emerging options. Drugs. 2010; 70(2):167-79. DOI: 10.2165/11532200-000000000-00000. View

11.

Bye A, Sjoblom B, Wentzel-Larsen T, Gronberg B, Baracos V, Hjermstad M . Muscle mass and association to quality of life in non-small cell lung cancer patients. J Cachexia Sarcopenia Muscle. 2017; 8(5):759-767. PMC: 5659054. DOI: 10.1002/jcsm.12206. View

12.

Cella D, Hahn E, Dineen K . Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual Life Res. 2002; 11(3):207-21. DOI: 10.1023/a:1015276414526. View

13.

Helbekkmo N, Sundstrom S, Aasebo U, Brunsvig P, von Plessen C, Hjelde H . Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer. 2007; 97(3):283-9. PMC: 2360329. DOI: 10.1038/sj.bjc.6603869. View

14.

Marquis K, Debigare R, Lacasse Y, Leblanc P, Jobin J, Carrier G . Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002; 166(6):809-13. DOI: 10.1164/rccm.2107031. View

15.

Shaw A, Engelman J . ALK in lung cancer: past, present, and future. J Clin Oncol. 2013; 31(8):1105-11. PMC: 4209068. DOI: 10.1200/JCO.2012.44.5353. View

16.

Goodpaster B, Park S, Harris T, Kritchevsky S, Nevitt M, Schwartz A . The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol A Biol Sci Med Sci. 2006; 61(10):1059-64. DOI: 10.1093/gerona/61.10.1059. View

17.

Flotten O, Gronberg B, Bremnes R, Amundsen T, Sundstrom S, Rolke H . Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group. Br J Cancer. 2012; 107(3):442-7. PMC: 3405221. DOI: 10.1038/bjc.2012.284. View

18.

Fulster S, Tacke M, Sandek A, Ebner N, Tschope C, Doehner W . Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur Heart J. 2012; 34(7):512-9. DOI: 10.1093/eurheartj/ehs381. View

19.

Khalid U, Spiro A, Baldwin C, Sharma B, McGough C, Norman A . Symptoms and weight loss in patients with gastrointestinal and lung cancer at presentation. Support Care Cancer. 2006; 15(1):39-46. DOI: 10.1007/s00520-006-0091-0. View

20.

Baracos V, Reiman T, Mourtzakis M, Gioulbasanis I, Antoun S . Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. Am J Clin Nutr. 2010; 91(4):1133S-1137S. DOI: 10.3945/ajcn.2010.28608C. View